1. Home
  2. DRS vs EXAS Comparison

DRS vs EXAS Comparison

Compare DRS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRS
  • EXAS
  • Stock Information
  • Founded
  • DRS 1969
  • EXAS 1995
  • Country
  • DRS United States
  • EXAS United States
  • Employees
  • DRS N/A
  • EXAS N/A
  • Industry
  • DRS Military/Government/Technical
  • EXAS Medical Specialities
  • Sector
  • DRS Industrials
  • EXAS Health Care
  • Exchange
  • DRS Nasdaq
  • EXAS Nasdaq
  • Market Cap
  • DRS 9.7B
  • EXAS 11.0B
  • IPO Year
  • DRS N/A
  • EXAS N/A
  • Fundamental
  • Price
  • DRS $34.74
  • EXAS $67.40
  • Analyst Decision
  • DRS Strong Buy
  • EXAS Strong Buy
  • Analyst Count
  • DRS 6
  • EXAS 18
  • Target Price
  • DRS $46.83
  • EXAS $72.44
  • AVG Volume (30 Days)
  • DRS 1.4M
  • EXAS 3.0M
  • Earning Date
  • DRS 10-29-2025
  • EXAS 11-03-2025
  • Dividend Yield
  • DRS 1.04%
  • EXAS N/A
  • EPS Growth
  • DRS 33.93
  • EXAS N/A
  • EPS
  • DRS 0.99
  • EXAS N/A
  • Revenue
  • DRS $3,569,000,000.00
  • EXAS $3,082,033,000.00
  • Revenue This Year
  • DRS $12.03
  • EXAS $16.68
  • Revenue Next Year
  • DRS $6.76
  • EXAS $12.36
  • P/E Ratio
  • DRS $34.90
  • EXAS N/A
  • Revenue Growth
  • DRS 12.27
  • EXAS 14.47
  • 52 Week Low
  • DRS $28.17
  • EXAS $38.81
  • 52 Week High
  • DRS $49.31
  • EXAS $72.81
  • Technical
  • Relative Strength Index (RSI)
  • DRS 26.75
  • EXAS 64.65
  • Support Level
  • DRS $34.50
  • EXAS $66.14
  • Resistance Level
  • DRS $36.08
  • EXAS $69.08
  • Average True Range (ATR)
  • DRS 1.11
  • EXAS 2.28
  • MACD
  • DRS -0.13
  • EXAS -0.23
  • Stochastic Oscillator
  • DRS 9.51
  • EXAS 49.47

About DRS Leonardo DRS Inc.

Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: